Prevention of Human Immunodeficiency Virus-Related Opportunistic Infections in France: A Cost-Effectiveness Analysis

Yazdanpanah, Y.; Goldie, S.J.; Paltiel, A.D.; Losina, E.; Coudeville, L.; Weinstein, M.C.; Gerard, Y.; Kimmel, A.D.; Zhang, H.; Salamon, R.; Mouton, Y.; Freedberg, K.A.
January 2003
Clinical Infectious Diseases;1/1/2003, Vol. 36 Issue 1, p86
Academic Journal
A simulation model of human immunodeficiency virus (HIV) disease, which incorporated French data on the progression of HIV disease in the absence of antiretroviral therapy and on cost, was used to determine the clinical impact and cost-effectiveness of different strategies for the prevention of opportunistic infections in French patients who receive highly active antiretroviral therapy (HAART). Compared with use of no prophy-laxis, use of trimethoprim-sulfamethoxazole (TMP-SMZ) increased per-person lifetime costs from &Jucky;185,600 to &Jucky;187,900 and quality-adjusted life expectancy from 112.2 to 113.7 months, for an incremental cost-effectiveness ratio of &Jucky;18,700 per quality-adjusted life-year (&Jucky;/QALY) gained. Compared with use of TMP-SMZ alone, use of TMP-SMZ plus azithromycin cost &Jucky;23,900/QALY gained; adding fluconazole cost an additional &Jucky;54,500/QALY gained. All strategies that included oral ganciclovir had cost-effectiveness ratios that exceeded &Jucky;100,000/QALY gained. In the era of HAART, on the basis of French data, prophylaxis against Pneumocystis carinii pneumonia, toxoplasmic encephalitis, and Mycobacterium avium complex bacteremia is cost-effective. Prophylaxis against fungal and cytomegalovirus infections is less cost-effective than are other therapeutic options for HIV disease and should remain of lower priority.


Related Articles

  • Impact of Daily Cotrimoxazole on Clinical Malaria and Asymptomatic Parasitemias in HIV-Exposed, Uninfected Infants. Davis, Nicole L.; Barnett, Eric J.; Miller, William C.; Dow, Anna; Chasela, Charles S.; Hudgens, Michael G.; Kayira, Dumbani; Tegha, Gerald; Ellington, Sascha R.; Kourtis, Athena P.; van der Horst, Charles; Jamieson, Denise J.; Juliano, Jonathan J. // Clinical Infectious Diseases;8/1/2015, Vol. 61 Issue 3, p368 

    Background. Cotrimoxazole preventive therapy (CPT) is recommended for all human immunodeficiency virus (HIV)-exposed infants to avoid opportunistic infections. Cotrimoxazole has antimalarial effects and appears to reduce clinical malaria infections, but the impact on asymptomatic malaria...

  • Diagnosis and management of HIV infection. Palfreeman, Adrian; Fisher, Martin // British Journal of Hospital Medicine (17508460);Mar2011, Vol. 72 Issue 3, p146 

    The article outlines the management of human immunodeficiency virus (HIV) infection in Great Britain, and offers information on its diagnosis and treatment. It explores the consequences of late diagnosis as pointed by the Health Protection Agency (HPA), and explains how to reduce instances of...

  • Bacterial battles. Dixon, Bernard // BMJ: British Medical Journal (International Edition);9/16/95, Vol. 311 Issue 7007, p756 

    Focuses on the effect of technological changes on the opportunistic characteristics of bacteria. Concerns on opportunisties for the proliferation of spoilage organisms in convenience packing of foods.

  • Combination of Ritonavir and Saquinavir Reduces HIV Viral Load. Cohen, Calvin J. // American Family Physician;11/15/1996, Vol. 54 Issue 7, p2288 

    Focuses on a results of multicenter, randomized study of 136 patients with human immunodefidiency virus (HIV) infection which indicate that the combination of two protease inhibitors, ritonavir & saquinavir, reduces the HIV viral load. How the study was conducted to patients.

  • Progress in efforts to prevent the spread of HIV infection among youth. Moore, J.R.; Daily, L. // Public Health Reports;Nov/Dec91, Vol. 106 Issue 6, p678 

    Discusses a program launched by the Centers for Disease Control (CDC) in 1987 to help schools and other agencies that serve youth to provide effective health education to prevent the spread of the human immunodeficiency virus (HIV). Percentage of persons reported with acquired immunodeficiency...

  • Increasing the involvement of national and regional racial and ethnic minority organizations in... Holman, P.B.; Jenkins, W.C. // Public Health Reports;Nov/Dec91, Vol. 106 Issue 6, p687 

    Comments on a five year grant program initiated by the Centers for Disease Control (CDC) in 1988 of HIV prevention efforts by national racial and ethnic minority organizations and regional consortia of racial and ethnic minority organizations. Number of organizations receiving first year...

  • Attack on AIDS. Fleming Jr., Harris // Drug Topics;7/6/98, Vol. 142 Issue 13, p60 

    Examines the efforts of drugstore chains in their fight against human immunodeficiency virus (HIV) in the United States. Efforts of StatScript Pharmacy and Walgreen Company to fight HIV; Comments from Walgreens national director-pharmacy operations Phil Burgess.

  • Alcohol use and risk for HIV infection. Strunin, Lee; Hingson, Ralph // Alcohol Health & Research World;1993, Vol. 17 Issue 1, p35 

    Discusses alcohol use and the risk for HIV infection. The assertion that alcohol use may increase the likelihood of HIV infection by decreasing the likelihood of condom use during intercourse; Recommendation that both HIV prevention programs and alcohol education programs should warn about the...

  • An epidemic like any other? Rights and responsibilities in HIV prevention. Danziger, Renee // BMJ: British Medical Journal (International Edition);4/27/96, Vol. 312 Issue 7038, p1083 

    Discusses the clinical, epidemiological and social changes involved in the approach to HIV prevention worldwide. Factors contributing to `normalization' of AIDS; Growing recognition of social responsibility in AIDS prevention; Rights and responsibilities in HIV prevention.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics